EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Drug hypersensitivity and eosinophilia: The decisive role of p‐i stimulation

Werner J Pichler iD, Lester Thoo iD, Daniel Yerly iD

Allergy · 2023

DOI: 10.1111/all.15795 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Allergy, 2023. Verfasst von Werner J Pichler und 2 weiteren Autor:innen. Beteiligte Einrichtung: ADR-AC GmbH, Bern, Switzerland. Hauptthemen laut MEDLINE: Drug Hypersensitivity, Eosinophilia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 88 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eosinophilia is a common finding in drug hypersensitivity reactions (DHR). Its cause is unclear, as neither antigen/allergen‐driven inflammation nor clonal expansion is involved. Most delayed‐DHRs are due to p‐i ( p harmacologic interaction of drugs with i mmune receptors). These are off‐target activities of drugs with immune receptors that result in various types of T‐cell stimulation, some of which involve excessive IL‐5 production. Functional and phenotypic studies of T‐cell clones and their TCR‐transfected hybridoma cell lines revealed that some p‐i‐induced drug stimulations occur without CD4/ CD8 co‐receptor engagement. The CD4/CD8 co‐receptors link Lck (lymphocyte‐specific protein tyrosine kinase) and LAT (linker for activation of T cells) to the TCR. Alteration of Lck or LAT can result in a TCR signalosome with enhanced IL‐5 production. Thus, if a more affine TCR‐[drug/peptide/HLA] interaction allows bypassing the CD4 co‐receptor, a modified Lck/LAT activation may lead to a TCR signalosome with elevated IL‐5 production. This “IL‐5‐TCR‐signalosome” hypothesis could also explain eosinophilia in superantigen or allo‐stimulation (graft‐versus‐host disease), in which evasion of CD4/CD8 co‐receptors has also been described. It may open new therapeutic possibilities in certain eosinophilic diseases by directly targeting the IL‐5‐TCR signalosome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug HypersensitivityEosinophiliaHumansReceptors, Antigen, T-CellInterleukin-5T-LymphocytesCD8 AntigensCD4 AntigensLymphocyte Specific Protein Tyrosine Kinase p56(lck)

Stichwörter der Autor:innen

CD4/CD8 co-receptorsIL-5TCR signalosomedrug hypersensitivityeosinophiliap-i concept

Substanzen

Receptors, Antigen, T-CellInterleukin-5CD8 AntigensCD4 AntigensLymphocyte Specific Protein Tyrosine Kinase p56(lck)

Autor:innen und Institutionen

  • ADR-AC GmbH, Bern, Switzerland.

ORCID-Profile: Werner J Pichler, Lester Thoo, Daniel Yerly

Zitieren

APA

Pichler, W. J., Thoo, L., & Yerly, D. (2023). Drug hypersensitivity and eosinophilia: The decisive role of p‐i stimulation. Allergy. https://doi.org/10.1111/all.15795

Vancouver

Pichler WJ, Thoo L, Yerly D. Drug hypersensitivity and eosinophilia: The decisive role of p‐i stimulation. Allergy. 2023. doi:10.1111/all.15795

BibTeX
@article{Pichler2023,
  author = {Pichler, Werner J and Thoo, Lester and Yerly, Daniel},
  title = {Drug hypersensitivity and eosinophilia: The decisive role of p‐i stimulation},
  journal = {Allergy},
  year = {2023},
  doi = {10.1111/all.15795}
}
Kostenlos starten →